All News
GWAS Reveals Shared Susceptibility Locus Between RA and SLE
While the phenotypes of RA and SLE are quite different, genome-wide association studies (GWAS) performed in the past have shown a genetic overlap between both.
Read ArticleNetrin-1 May Promote Lung Fibrosis in Scleroderma
Mechanisms underlying the pulmonary fibrosis of systemic sclerosis are poorly understood, yet are the focus of both research and new drug development.
Read ArticleRheumNow Week in Review – 22 April 2016
Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.
Read Article
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Articleα Defensin Control of Inflammation
Alpha defensins are released following apoptosis, necrosis, or netosis of human neutrophils. They are taken up by other cells and microbes, wherein they permeablize membranes and kill microbes and host cells. Thus, they augment the antimicrobial capacity of macrophages and at the same time inhibit the biosynthesis of proinflammatory cytokines.
Read Article
HLA-B*5801 Testing Needed in Asians and Blacks with Gout
Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).
Read ArticleLupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read ArticleCould Rheumatoid Synovium Be a Nursery for ACPA Producing Plasma Cells ?
One of the hallmarks of aggressive rheumatoid arthritis (RA) is presence of antibodies against citrullinated protein antigens (ACPA).
Read ArticleAltering the Microbiome May Benefit Lupus Patients
Lopez and colleagues from Spain have studied the gut microbiome of l
Read ArticleSclerostin Inhibition May Worsen Rheumatoid Arthritis
Sclerostin, an inhibitor of the Wnt/β-catenin pathway, negatively regulates osteoblast differentiation and has anti-anabolic effects on bone formation. Thus, inhibition of sclerostin is currently being studied as therapy for postmenopausal osteoporosis.
Read ArticleIL-6 Inhibition Makes News
Several new interleukin-6 inhibitors made headlines this week. While none of the new IL-6 inhibitors are soon to be approved and available, these studies may redefine the role of other non-TNF biologics in the future.
Read ArticleNovel Protein as a Potential Autoantigen in JIA
Juvenile idiopathic arthritis (JIA) is clearly not related to rheumatoid arthritis and until recently has no identifiabile autoantigen linked to JIA.
Read ArticleNew Classification Criteria for Macrophage Activation Syndrome
Systemic juvenile idiopathic arthritis (SoJIA) is one of the most common underlying etiologies to the macrophage activation syndrome (MAS).
Read ArticleCBC Hidden Pearls
CBC…it’s easy as 123! The complete blood count (aka, CBC) is the most routine, but indispensable, of all medical assessments.
Read ArticleRWCS 2016 – Periodic Fever and Macrophage Activation Syndrome + Pregnancy in IBD
Pregnancy and Immune Modulating Therapies
Read ArticleFDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).
Read ArticleArthritis Foundation Awards $5.5 Million to 11 Investigators
The Arthritis Foundation announced that 11 scientists were selected out of 167 proposals as the 2015 Scientific Discovery Awardees for their innovations toward finding a cure for arthritis and related diseases.
Read ArticleShould You Avoid Pneumococcal Vaccine in CAPS and Behcet's Patients
Althought EULAR currently recommends the pneumococcal vaccine be given to patients with inflammatory rheumatic diseases and the Centers for Disease Control and Prevention (CDC) recommends the vaccine in patients treated with immunosuppressive drugs, a recent brief report suggests it be
Read ArticleNIH-Funded Trials Down, While Industry Trials Increase
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Read ArticleOminous Outcomes for Lupus Nephritis
Hanly and coworkers have reported the results of a large lupus cohort study involving 1827 patients. SLE patients were enrolled early in their disease (0.5 years) and were followed for a mean of 4.6 years.
Read Article